Product information and disease descriptionProduct descriptionProduct information
Effect of Envudeucitinib on quality measures
9 evidence topics · 3 sources
MIPS Quality ID 410: description, measure type, and denominator
| Field | Specification text |
|---|---|
| Measure type | “Intermediate Outcome – High Priority” |
| Telehealth | “TELEHEALTH ELIGIBLE: This measure is appropriate for and applicable to the telehealth setting.” |
MIPS Quality ID 410: numerator benchmarks for PGA, BSA, PASI, and DLQI
MIPS Quality ID 410: six-month treatment period and denominator exception
MIPS Quality ID 410: reference list of systemic medications, oral agents
| Brand name | Chemical name | Mechanism of action or type of systemic | Indication |
|---|---|---|---|
| Sotyktu | “deucravacitinib” | “Inhibits tyrosine kinase 2 (TYK2)” | “Psoriasis” |
| Otezla | “apremilast” | “Blocks phosphodiesterase-4” | “Psoriasis, Psoriatic arthritis” |
| Neoral | “cyclosporine, modified” | “Blocks lymphocytes (T cells) and lymphokines” | “Psoriasis” |
| Jylamvo | “methotrexate” | “Inhibits dihydrofolic acid reductase” | “Psoriasis” |
| Soriatane | “acitretin” | “Unknown; activates retinoid receptors” | “Psoriasis” |
MIPS Quality ID 410: rationale and clinical recommendation statements on treatment goals
MIPS Quality ID 485: description, measure type, denominator, and numerator for itch severity
MIPS Quality ID 485: rationale on pruritus in psoriasis
QCDR measure AAD15: appropriate assessment and treatment of severe psoriasis
QCDR measure AAD8: patient-reported quality of life in chronic skin conditions including psoriasis
HEDIS and NCQA measures for psoriasis
No evidence found.
Product-specific effect of envudeucitinib on quality measure performance
No evidence found.